Immunization

Investigators explore how long COVID impacts trust in vaccines, revealing diverse patient experiences and the need for better communication in public health.

A study shows young adults with 3 or more COVID-19 vaccine doses experience fewer symptoms, emphasizing vaccination's critical role in public health.

As misinformation persists, health experts and research point to pharmacists as key communicators in building trust and boosting immunization rates.

Using the PhotoVoice methodology, researchers conduct a study exploring Latinx adolescents’ preferences and the impacts of the COVID-19 pandemic and vaccine messaging.

With uncertainty in dosing recommendations, researchers aim to assess the efficacy of pneumococcal conjugate vaccines for the pediatric population.

Amid recent measles outbreaks in Texas and Ohio, researchers aim to understand MMR vaccine coverage following postelimination outbreaks throughout the country.

Further, after the introduction of the pneumococcal conjugate vaccine 10, investigators note a decrease of infections caused by multidrug resistance infection.

The vote for state and local jurisdictions requiring a prescription for administration of COVID-19 vaccines failed after a tiebreaker vote from the committee chair.

The recommendations are provided through the West Coast Health Alliance and pull from guidance from the American Academy of Pediatrics and other organizations.

However, a large majority of parents in the US believe routine childhood vaccines, such as the measles, mumps, and rubella vaccine and polio vaccine, are safe and important.

Using the Vaccine Adverse Event Reporting System database, researchers address adverse events following pneumococcal vaccination, as well as the association between adverse events and vaccine administration.

Merck’s pneumococcal 21-valent conjugate vaccine was noninferior to the pneumococcal 23-valent polysaccharide vaccine for all 12 shared serotypes and superior to 9 unique serotypes.

Due to an increased risk of vaccine-preventable diseases, researchers explore pneumococcal, COVID-19, and influenza vaccine coverage among people living with HIV in Belgium.

As the 2025-2026 respiratory season approaches, the CDC’s Advisory Committee on Immunization Practices has not met and voted on guidelines for COVID-19 vaccines.

CVS will not offer COVID-19 vaccines in Massachusetts, Nevada, and New Mexico.

Pharmacists navigate complex immunization challenges and address parental concerns and misinformation while advocating for streamlined vaccine access and adherence to evolving guidelines.

Childhood immunization guidance in the US faces confusion as the AAP and CDC diverge on COVID-19 vaccine recommendations, impacting parents and providers.

Among older adults with Medicare, researchers investigated national influenza vaccination patterns by race, education level, and rurality.

Researchers explored the impact of PCV10 on the distribution of invasive pneumococcal disease serotypes among patients in Lithuania.

The approved vaccines include Novavax’s Nuvaxovid and Moderna’s Spikevax and mNexspike.

The approval covers Pfizer and BioNTech’s LP.8.1-adapted monovalent COVID-19 vaccine, which is also indicated for patients aged 5 to 64 with at least 1 underlying condition.

Through considerations regarding cost, scalability, safety, and regulations, researchers provided an end-to-end perspective on microneedle-based vaccine strategies.

Among participants in the CATCH trial, researchers explored the relationship between HPV vaccination and incidence of infection.

As Walgreens senior director of immunizations, Samantha Picking, PharmD, delved into the evolution of pharmacies’ immunization services as well as their dedication to vaccine uptake.

Amid increased concerns of vaccine hesitancy among the parents of pediatric patients, researchers sought the most effective communication methods to curb this growing phenomenon.